Surviving Twenty Years to Bone and Liver Metastatic Breast Cancer: A Case Reported by Treating Oncologists and the Patient Herself

Autor: Maria Rosaria Valerio, Vittorio Gebbia, Dario Piazza, Giuseppina Campisi, Eleonora D’Agati, Monica Bazzano

Publikováno v: Case Reports in Oncology, Vol 17, Iss 1, Pp 1174-1182 (2024)

Introduction: Metastatic breast cancer (MBC) presents an enduring and significant challenge for affected women, requiring sustained commitment over the years. Case Presentation: This paper presents a case of a woman affected by bone and visceral MBC

Externí odkaz: https://doaj.org/article/c81de4df10564c879d6795ed2e89dca7

Correlation between sentinel lymph node biopsy and non-sentinel lymph node metastasis in patients with cN0 breast carcinoma: comparison of invasive ductal carcinoma and invasive lobular carcinoma

Autor: Calogero Cipolla, Simona Lupo, Nello Grassi, Giuseppe Tutino, Martina Greco, D’Agati Eleonora, Vittorio Gebbia, Maria Rosaria Valerio

Publikováno v: World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-7 (2024)

Abstract Background Some studies have suggested that axillary lymph node dissection (ALND) can be avoided in women with cN0 breast cancer with 1–2 positive sentinel nodes (SLNs). However, these studies included only a few patients with invasive lob

Externí odkaz: https://doaj.org/article/c66cef63ff374324962f1730149b4554

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Autor: Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia

Publikováno v: npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)

Abstract The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer (mTNBC), based on the results of phase III IMpassion130 trial. However, ‘real-w

Externí odkaz: https://doaj.org/article/eaf31c16c69a4f39924099b5b662aa2f

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Autor: Francesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Katia Cannita, Ugo De Giorgi, Fulvio Borella, Jennifer Foglietta, Anna Cariello, Antonella Ferro, Elisa Picardo, Marco Mitidieri, Valentina Sini, Simonetta Stani, Giuseppe Tonini, Daniele Santini, Nicla La Verde, Anna Rita Gambaro, Antonino Grassadonia, Nicola Tinari, Ornella Garrone, Giuseppina Sarobba, Lorenzo Livi, Icro Meattini, Giuliana D’Auria, Matteo Vergati, Teresa Gamucci, Mirco Pistelli, Rossana Berardi, Emanuela Risi, Francesco Giotta, Vito Lorusso, Lucia Rinaldi, Salvatore Artale, Marina Elena Cazzaniga, Fable Zustovich, Federico Cappuzzo, Lorenza Landi, Rosalba Torrisi, Simone Scagnoli, Andrea Botticelli, Andrea Michelotti, Beatrice Fratini, Rosa Saltarelli, Ida Paris, Margherita Muratore, Alessandra Cassano, Lorenzo Gianni, Valeria Gaspari, Enzo Maria Veltri, Federica Zoratto, Elena Fiorio, Maria Agnese Fabbri, Marco Mazzotta, Enzo Maria Ruggeri, Rebecca Pedersini, Maria Rosaria Valerio, Lorena Filomeno, Mauro Minelli, Paola Scavina, Mimma Raffaele, Antonio Astone, Roy De Vita, Marcello Pozzi, Ferdinando Riccardi, Filippo Greco, Luca Moscetti, Monica Giordano, Marcello Maugeri-Saccà, Alessandro Zennaro, Claudio Botti, Fabio Pelle, Sonia Cappelli, Flavia Cavicchi, Enrico Vizza, Giuseppe Sanguineti, Federica Tomao, Enrico Cortesi, Paolo Marchetti, Silverio Tomao, Iolanda Speranza, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

BackgroundIn triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the resu

Externí odkaz: https://doaj.org/article/9054ef5212d94639a5488c4656e59bc0

Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer

Autor: Calogero Cipolla, Antonio Galvano, Salvatore Vieni, Federica Saputo, Simona Lupo, Mario Latteri, Giuseppa Graceffa, Maria Rosaria Valerio

Publikováno v: World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-7 (2021)

Abstract Background Sentinel lymph node biopsy is the gold standard surgical technique for axillary staging in patients with clinically node-negative. However, it is still uncertain what is the optimal number of sentinel lymph nodes (SLNs) to be remo

Externí odkaz: https://doaj.org/article/01ea06f8472a492d9d91131b526a7af3